Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Becker

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
Molecules (Basel, Switzerland)|January 25, 2018
Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug DesignRosanna Meine, Walter Becker, Hannes Falke, et al.
Biochemical and Biophysical Research Communications|February 27, 2003
Unusual function of the activation loop in the protein kinase DYRK1AStephan Wiechmann, Hanna Czajkowska, Katrin de Graaf, et al.
European Journal of Medicinal Chemistry|September 8, 2018
Development of novel 2,4-bispyridyl thiophene-based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivativesSarah S Darwish, Mohammad Abdel-Halim, Mohamed Salah, et al.
The Biochemical Journal|March 14, 2003
Alternative splicing variants of dual specificity tyrosine phosphorylated and regulated kinase 1B exhibit distinct patterns of expression and functional propertiesSusanne Leder, Hanna Czajkowska, Barbara Maenz, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 2002
Effect of hyperinsulinemia and type 2 diabetes-like hyperglycemia on expression of hepatic cytochrome p450 and glutathione s-transferase isoforms in a New Zealand obese-derived mouse backcross populationGeorgia J Pass, Walter Becker, Reinhart Kluge, et al.
Biochemical and Biophysical Research Communications|January 1, 2003
DYRK1 is a co-activator of FKHR (FOXO1a)-dependent glucose-6-phosphatase gene expressionFlorian von Groote-Bidlingmaier, Dieter Schmoll, Hans Martin Orth, et al.
BMC Biochemistry|March 4, 2006
The protein kinase DYRK1A phosphorylates the splicing factor SF3b1/SAP155 at Thr434, a novel in vivo phosphorylation siteKatrin de Graaf, Hanna Czajkowska, Sabine Rottmann, et al.
Journal of Biomolecular NMR|March 23, 2018
Trimethylsilyl tag for probing protein-ligand interactions by NMRWalter Becker, Luke A Adams, Bim Graham, et al.
Molecules (Basel, Switzerland)|December 19, 2020
How to Separate Kinase Inhibition from Undesired Monoamine Oxidase A Inhibition-The Development of the DYRK1A Inhibitor AnnH75 from the Alkaloid HarmineAnne Wurzlbauer, Katharina Rüben, Ece Gürdal, et al.
Scientific Reports|July 27, 2017
DYRK1B mutations associated with metabolic syndrome impair the chaperone-dependent maturation of the kinase domainSamira Abu Jhaisha, Esti W Widowati, Isao Kii, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
Molecules (Basel, Switzerland)|January 25, 2018
Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug DesignRosanna Meine, Walter Becker, Hannes Falke, et al.
Biochemical and Biophysical Research Communications|February 27, 2003
Unusual function of the activation loop in the protein kinase DYRK1AStephan Wiechmann, Hanna Czajkowska, Katrin de Graaf, et al.
European Journal of Medicinal Chemistry|September 8, 2018
Development of novel 2,4-bispyridyl thiophene-based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivativesSarah S Darwish, Mohammad Abdel-Halim, Mohamed Salah, et al.
The Biochemical Journal|March 14, 2003
Alternative splicing variants of dual specificity tyrosine phosphorylated and regulated kinase 1B exhibit distinct patterns of expression and functional propertiesSusanne Leder, Hanna Czajkowska, Barbara Maenz, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 2002
Effect of hyperinsulinemia and type 2 diabetes-like hyperglycemia on expression of hepatic cytochrome p450 and glutathione s-transferase isoforms in a New Zealand obese-derived mouse backcross populationGeorgia J Pass, Walter Becker, Reinhart Kluge, et al.
Biochemical and Biophysical Research Communications|January 1, 2003
DYRK1 is a co-activator of FKHR (FOXO1a)-dependent glucose-6-phosphatase gene expressionFlorian von Groote-Bidlingmaier, Dieter Schmoll, Hans Martin Orth, et al.
BMC Biochemistry|March 4, 2006
The protein kinase DYRK1A phosphorylates the splicing factor SF3b1/SAP155 at Thr434, a novel in vivo phosphorylation siteKatrin de Graaf, Hanna Czajkowska, Sabine Rottmann, et al.
Journal of Biomolecular NMR|March 23, 2018
Trimethylsilyl tag for probing protein-ligand interactions by NMRWalter Becker, Luke A Adams, Bim Graham, et al.
Molecules (Basel, Switzerland)|December 19, 2020
How to Separate Kinase Inhibition from Undesired Monoamine Oxidase A Inhibition-The Development of the DYRK1A Inhibitor AnnH75 from the Alkaloid HarmineAnne Wurzlbauer, Katharina Rüben, Ece Gürdal, et al.
Scientific Reports|July 27, 2017
DYRK1B mutations associated with metabolic syndrome impair the chaperone-dependent maturation of the kinase domainSamira Abu Jhaisha, Esti W Widowati, Isao Kii, et al.
Pageof 7